For studing aberrant cellular immunity in malignant digestive tract diseases, Helix pomatia A hemagglutinin (HP) binding activity, a T cell surface marker, to peripheral lymphocytes was studied in patients with digestive tract cancer. In this paper, basic experiments on an assay method based on (125)I-labelled HP binding to neuraminidase-treated peripheral lymphocytes are described. HP was labelled with (125)I using the chlormine-T method, and the purif-ication of (125)I-labelled HP was achieved by agarose-aminocaproyl-D-galactosamine affinity chromatography. The results show that (125)I-labelled HP could specifically bind to neuraminidase-treated lymphocytes as cold HP. The optimum assay condition was determined to be: 1×10(6) neuraminidase-treated peripheral lymphocytes incubated with 0.4μg (125)I-labelled HP in 0.5 ml of reaction mixture at 25℃ for 90 min with gentle shaking. In addition, the effect of treatment of peripheral lymphocytes with neuraminidase on E-rosette formation was studied. Enhancement of E-rosette formation by neuraminidase-treatment was not statistically significant.
Helix pomatia A hemagglutinin